Enrolling by invitation NCT06793306
A Study Comparing the Differences Between Young and Non-young Breast Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Age, combination therapy.
- Who it may be relevant to
- Registry conditions: Breast Cancer. Basic parameters: 18 years — 75 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
To collect data on diagnosis, treatment, survival prognosis, and intrinsic molecular detection of breast cancer in China from January 2000 to December 2024.Compare the difference between young and non-young breast cancer.
Interventions
- Other Age
Breast cancer patients were divided into young breast cancer and non-young breast cancer by age 35 - Other combination therapy
To observe and compare the difference in diagnosis, combined treatment and prognosis between young and non-young breast cancer
Primary outcome measures
- Overall survival rate [Time frame: 10-year]
Secondary outcome measures (1)
- invasive disease-free survival rate [Time frame: 10-year]
Eligibility criteria
Inclusion criteria
- During the period from January 2000 to December 2024, the first breast cancer diagnosed and treated in several hospitals in China was in the age range of 18-75 years.
Exclusion criteria
- Breast cancer patients under 18 years of age or over 75 years of age; Combined with other malignant tumors; Patients with chronic infectious diseases or chronic infectious diseases; Patients with severe comorbidities, with serious dysfunction of vital organs (heart, liver, kidney); Known history of human immunodeficiency virus; The investigator concluded that patients should not be included in other conditions of this trial.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Cancer Hospital, Chinese Academy of Medical Sciences — Beijing
Identifiers
NCT: NCT06793306 · NCC5093